Targeting mangiferin loaded N-succinyl chitosan-alginate grafted nanoparticles against atherosclerosis - A case study against diabetes mediated hyperlipidemia in rat

Mangiferin (MGF), from Mangifera indica is well reported for its hypoglycemic activity and hypolipidemic activity. However, MGF suffers therapeutic limitation due to poor solubility causing disparaging bioavailability. Herein to address this problem, we have incorporated MGF in alginate grafted N-succinylated chitosan (NSC) nanomatrix. Characterization by molecular docking, FT-IR and 2D-NMR (COSY) has revealed that MGF could reinforce interaction with NSC. The -OH and -CH2OH groups of MGF may set interactions with pyranosic -OH, -CH2OH, -NH2 (or -NH-succinyl and -COOH-succinyl) of NSC. The NSC-MGF nanoconjugate revealed a spherical particle geometry of 100 similar to 200 nm size. The encapsulated MGF showed 100% release in vitro. In vivo, NSC-MGF nanoconjugate revealed blood glucose lowering from 300 mg/dL to similar to 90 mg/dL as well as similar to 37% lowering of total plasma cholesterol. This is well comparative to the earlier reports which acknowledged only 1 similar to 36% lowering of plasma cholesterol with MGF. Furthermore, NSC-MGF lowered serum trigyceride to similar to psi 61%, while in earlier studies, only 10 similar to 40% serum triglycerides reduction was found with solitary MGF.

Automated summary

The study combined mangiferin with alginate grafted N-succinylated chitosan to form a nanoconjugate, which improved bioavailability by enhancing interaction with chitosan. In in vivo experiments, the nanoconjugate effectively lowered blood glucose and lipid levels, showing promising therapeutic potential.